Physician profile
Kenneth E Brown
NPI 1497779755
$16,929.24
in general payments reported to CMS, 2019-2025
52 companies · $2,583 in 2025
The $2,583 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,531 · 2020: $2,616 · 2021: $1,917 · 2022: $1,887 · 2023: $2,758 · 2024: $2,637 · 2025: $2,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,978.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,281.63 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $2,154.47 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,927.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,564.64 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $1,029.81 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $772.99 | 2019-2025 | Jardiance, Ofev |
| Amgen INC. | $735.39 | 2019-2025 | Repatha, Otezla, Evenity |
| Otsuka America Pharmaceutical, INC. | $727.79 | 2019-2025 | Rexulti, Nuedexta |
| Allergan, INC. | $712.16 | 2019-2020 | |
| Lilly USA, LLC | $695.62 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $608.09 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $370.40 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Axsome Therapeutics, INC. | $355.17 | 2024-2025 | Auvelity |
| Abbott Laboratories | $317.89 | 2020-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $314.71 | 2020-2025 | Nexletol |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.